Brief: Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
Jan 7 (Reuters) - Solid Biosciences Inc SLDB.O :
* SOLID BIOSCIENCES ANNOUNCES FDA IND CLEARANCE FOR
FIRST-IN-INDUSTRY DUAL ROUTE OF ADMINISTRATION GENE THERAPY TO
TREAT BOTH NEUROLOGIC AND CARDIAC MANIFESTATIONS OF FRIEDREICH’S
ATAXIA
* SOLID BIOSCIENCES INC: PHASE 1B CLINICAL TRIAL INITIATION
EXPECTED IN 2H 2025
Source text: ID:nGNXbQwqFD
Further company coverage: SLDB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Solid Biosciences
See all newsSolid Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Solid Biosciences Inc expected to post a loss of 48 cents a share - Earnings Preview
Solid Biosciences Q2 net loss widens on higher R&D costs
Marketing Agreement To Advance Gene Therapy Delivery And Analytics
Solid Biosciences Q1 net loss widens on higher R&D costs